MBB Public Markets I LLC Purchases New Holdings in Boston Scientific Corporation $BSX

Key Points

• MBB Public Markets I LLC invested approximately $316,000 in Boston Scientific Corporation, acquiring 3,128 shares in the first quarter.
• Insiders at Boston Scientific, including Director Edward J. Ludwig and EVP Joseph Michael Fitzgerald, have sold significant shares, totaling over $18 million in value over the last ninety days.
• The company's latest earnings report revealed a 22.8% increase in revenue year-over-year, with a quarterly earnings per share of $0.75, surpassing estimates.

MBB Public Markets I LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,128 shares of the medical equipment provider's stock, valued at approximately $316,000.

Other large investors have also added to or reduced their stakes in the company. Investment Management Corp VA ADV acquired a new position in Boston Scientific during the fourth quarter worth $25,000. Sunbeam Capital Management LLC bought a new stake in Boston Scientific during the fourth quarter worth $26,000. 1248 Management LLC bought a new stake in Boston Scientific during the first quarter worth $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific during the first quarter worth $27,000. Finally, Ameriflex Group Inc. bought a new stake in Boston Scientific during the fourth quarter worth $31,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX traded down $1.63 during trading hours on Friday, hitting $102.71. The company had a trading volume of 10,541,837 shares, compared to its average volume of 6,118,901. The firm has a market cap of $152.19 billion, a price-to-earnings ratio of 61.14, a PEG ratio of 2.51 and a beta of 0.65. The business has a fifty day moving average of $104.86 and a 200-day moving average of $102.26. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the topic of several analyst reports. Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $118.00 to $125.00 in a research report on Monday. Raymond James Financial boosted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Truist Financial boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Finally, Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $118.04.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $18,397,457 in the last three months. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.